WeChat Mini Program
Old Version Features

Long-Term Outcomes of a Phase I Study with UV1, a Second Generation Telomerase Based Vaccine, in Patients with Advanced Non-Small Cell Lung Cancer

Wenche Rasch,Paal Brunsvig,Martha Nyakas, Clau Reisse,Jon Amund Kyte,Hedvig Vidarsdotter Juul,Steinar Aamdal,Gustav Gaudernack,Else Marit Inderberg

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）

Cited 26|Views5
Key words
non-small cell lung cancer,human telomerase reverse transcriptase,peptide,vaccine monotherapy,dose response,clinical efficacy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined